Top Medical News
Hypothyroidism, lower FT4 levels tied to greater T2D risk
6 hours ago
People with hypothyroidism and lower free thyroxine (FT4) levels in the reference range have a higher risk of type 2 diabetes (T2D), suggests a recent study.
Dextrose gel reduces need for intravenous fluids in babies with asymptomatic hypoglycaemia
11 hours ago
In neonates who have asymptomatic hypoglycaemia in the first 48 hours of life, administering dextrose gel is useful and minimizes requirement for intravenous fluids, as shown in a study.
Intensive BP management reduces CVD deaths in overweight, obese patients
Stephen Padilla, Yesterday
Intensive management of blood pressure (BP) leads to a significant reduction in cardiovascular events in overweight, obese I, and obese II patients without elevating safety risks, a study has shown.
Keto diet: Is there good evidence in MS?
Elvira Manzano, Yesterday
A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.
Canagliflozin improves HF symptoms, QoL regardless of diabetes status
2 days ago
A recent meta-analysis offers new proof of different canagliflozin doses for hypertension management in patients with type 2 diabetes mellitus (T2DM) complicated by hypertension. However, low-density lipoprotein cholesterol (LDL-C) and the risk of urinary tract infection must be observed.
The current blood glucose monitor requires a disposable test strip and a small drop of blood.
3 days ago
The risks of cardiovascular disease (CVD) mortality appear to be higher among adults with elevated late nonfasting plasma glucose (PG) levels independently of glycated haemoglobin (HbA1c), a recent study reports.
Special Reports
Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
Clinical benefits of flash glucose monitoring with FreeStyle Libre™
15 Sep 2021
Various studies have shown the beneficial effects of the FreeStyle Libre™ flash glucose monitoring system for the continuous monitoring of glucose levels in type 1 and type 2 diabetes (T1D and T2D) patients. While clinical trials have demonstrated a reduced time in hypoglycaemia, fewer hypoglycaemic events per day, and significant reduction in glycated haemoglobin (HbA1c), real-world data have shown improved glycaemic control in these patients.
Optimising glycaemic control with FreeStyle Libre™ for better patient management
15 Sep 2021
The FreeStyle Libre™ flash glucose monitoring system includes a sensor which automatically measures and continuously stores up to 8 hours of glucose readings, allowing patients to monitor their glucose levels without the need for painful finger pricks. Physicians play an important role in reviewing and analysing glucose data that is available through LibreView to support patient management.
Continuous glucose monitoring versus self-monitoring of blood glucose: A healthcare professional’s perspective
26 Aug 2021
Technological advancements have improved glucose monitoring and diabetes care, as well as empowered patients in self-care. The introduction of continuous glucose monitoring systems (CGM), such as the Abbott FreeStyle LibreTM, offers patients an alternative and additional advantages to self-monitoring of blood glucose (SMBG).
Conference Reports
Elevated BMI may up recurrent AF risk
Roshini Claire Anthony, 13 Apr 2022

Among patients who had previously undergone ablation for atrial fibrillation (AF), the risk of recurrent AF increased with rising body mass index (BMI), according to a study from Denmark presented at EHRA 2022.

Resistance exercise could improve sleep duration, efficiency
Roshini Claire Anthony, 04 Apr 2022

Individuals at elevated cardiovascular disease risk (overweight/obese, increased blood pressure levels) may improve the duration and efficiency of their sleep through regular resistance exercise regimens, according to a study presented at the EPI Lifestyle Scientific Sessions 2022.

Could drinking wine with meals reduce T2D risk?
Roshini Claire Anthony, 01 Apr 2022

Individuals who consume a moderate amount of wine with meals may have a reduced risk of new-onset type 2 diabetes (T2D), according to a study presented at the EPI Lifestyle Scientific Sessions 2022.

Early menopause tied to increased dementia risk
Roshini Claire Anthony, 15 Mar 2022

Individuals who experience menopause before age 50 years may be at an elevated risk of developing dementia, according to results of a UK study presented at the EPI Lifestyle Scientific Sessions 2022.

Low-dose aspirin does not stave off dementia
Roshini Claire Anthony, 10 Dec 2021

A daily 100 mg dose of aspirin for 7 years did not reduce the risk of dementia in individuals with diabetes and no history of cardiovascular disease (CVD), according to results of the ASCEND* study presented at AHA 2021.

Empagliflozin beneficial and well tolerated in acute heart failure
Christina Lau, 06 Dec 2021

Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.

Bempedoic acid improves lipid, glycaemic parameters regardless of metabolic status
Audrey Abella, 22 Nov 2021
Data presented at AHA 2021 demonstrated the efficacy and safety of bempedoic acid for improving lipid and glycaemic parameters and hsCRP irrespective of metabolic status.